Angiotech partner submits final module for Taxus Liberte coronary stent system application

By Ted A. Knutson

Washington, March 8 - Angiotech Pharmaceuticals, Inc. said Wednesday that its corporate partner, Boston Scientific Corp., has submitted to the Food and Drug Administration the final module of Boston Scientific's Pre-Market Approval application for its Taxus Liberte paclitaxel-eluting coronary stent system. The Taxus Liberte system is Boston Scientific's next-generation drug-eluting stent system.

The third and final PMA module contains nine-month data from the Atlas clinical trial, a global, multi-center, pivotal study designed to support FDA approval of the Taxus Liberte system in the United States.

Boston Scientific launched its Taxus Liberte stent system in select international markets in January 2005 and received the CE Mark in Europe in September 2005. In April 2005, Boston Scientific received FDA approval for its Liberte bare-metal coronary stent system.

Boston Scientific will announce nine-month data from its pivotal Atlas clinical trial at the EuroPCR conference in May.

Boston Scientific acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat its coronary stent products and has co-exclusive rights to other vascular and non-vascular products.

Angiotech is a Vancouver, B.C.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.